Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

University of Rostock20 enrolled

Overview

Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Hymenoptera Venom Allergy

Interventions

Hymenoptera venomBIOLOGICAL

Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).

Eligibility

Sex: ALLMin age: 16 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosed hymenoptera venom allergy * No previous treatments for hymenoptera venom allergy Exclusion Criteria: * Treatment with immunosuppressive agents * Any malignant disease * Infections within 1 week prior to the initiation of the treatment

Locations (1)

University of Rostock

Rostock, Mecklenburg-Vorpommern, Germany

Outcomes

Primary Outcomes

Number of myeloid DC and plasmacytoid DC in peripheral blood

Time frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy

Secondary Outcomes

Surface molecule expression on myeloid DC and plasmacytoid DC

Time frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.